PeerVoice Endocrinology & Metabolic Disorders Audio

Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.

Visit https://www.peervoice.com/HPE860 to view the entire programme with slides. After completing “Carel le Roux, MD, PhD - Prioritising Obesity Care in Our Clinical Practices: Why We Must and How We Can”, participants will be able to: Apply best practices for the screening and formal diagnosis of obesity as a chronic disease; Identify patients who would benefit from treatment or referral for management of obesity; and Evaluate current and emerging strategies for treating obesity as a chronic disease.

Visit https://www.peervoice.com/TBP860 to view the entire programme with slides. After completing “Meena B. Bansal, MD, FAASLD - The Many Faces of MASH: Recognising Risk, Improving Identification, and Maximising Management in the Primary Care Setting”, participants will be able to: Discuss the pathogenesis and metabolic drivers of metabolic dysfunction-associated steatohepatitis (MASH); Apply risk stratification scores for liver fibrosis; and Develop guideline-recommended management plans for patients with MASH.

Visit https://www.peervoice.com/SCT860 to view the entire programme with slides. After completing “Andreea Ciudin, MD, PhD - Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on the Modernisation of Obesity Care”, participants will be able to: Explain the rationale for screening for and formally diagnosing obesity as a chronic disease; Apply best practices for communication with people who have obesity about the associated risks and treatment options; and Apply a multidisciplinary, multispeciality approach to obesity care.

Visit https://www.peervoice.com/MPR860 to view the entire programme with slides. After completing “Lise Lotte Gluud, MD - Following the Evidence-Based Road: Improving Care for MASH Through Use of Clinical Care Pathways in Primary Care”, participants will be able to: Apply strategies to identify patients who warrant additional screening for metabolic dysfunction-associated steatohepatitis (MASH) based on clinical suspicion and imaging; Discuss serum biomarkers and non-invasive screening techniques for fibrosis; and Describe guideline-recommended strategies for the management of comorbidities in patients with MASH.

Visit https://www.peervoice.com/SUE860 to view the entire programme with slides. After completing “Tina Vilsbøll, MD, DMSc - Overcoming Barriers to Basal Insulin in T2DM: Appreciating the Preferences and Perspectives of Patients With T2DM ”, participants will be able to: Explain the rationale for timely initiation of basal insulin treatment in patients with type 2 diabetes mellitus (T2DM); Assess common patient- and provider-level barriers to the use of basal insulin therapy; and Evaluate the current evidence for once-weekly insulins in the management of T2DM.

Visit https://www.peervoice.com/EDT860 to view the entire programme with slides. After completing “Paolo Sbraccia, MD, PhD - Providing State of the Art Care for People With Obesity: Can We Break Free From the Status Quo?”, participants will be able to: Apply guidelines and recommendations for accurate and timely diagnosis of obesity; Manage obesity as a specific, treatable, adiposity-based chronic disease; and Propose management plans for obesity in collaboration with patients through a shared decision-making approach.

Visit https://www.peervoice.com/SXQ860 to view the entire programme with slides. After completing “Harpreet Bajaj, MD, MPH - Innovating Our Approach to the Initiation of Insulin in T2DM: The Why and the How”, participants will be able to: Evaluate the current guideline-recommended place of basal insulin therapy in the management of type 2 diabetes mellitus (T2DM); Identify common contributors to delayed initiation of basal insulin treatment for patients with T2DM; and Analyse current efficacy and safety data for once-weekly insulins in the management of T2DM.

Visit https://www.peervoice.com/VSB860 to view the entire programme with slides. After completing “Melanie J. Davies, CBE, FRCP, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies”, participants will be able to: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal complications in patients with T2DM; and Propose practical approaches to address cost and clinical effectiveness for patients with T2DM.

Visit https://www.peervoice.com/FZR860 to view the entire programme with slides. After completing “Mansoor Husain, MD - Integrating GLP-1 RAs Into Our Cardiology Care Pathways: Who, When, and Why?”, participants will be able to: Identify the current place in therapy for GLP-1 receptor agonists (RAs) within guideline-recommended treatment algorithms for type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety data related to the effects of GLP-1 RAs on glycaemia, cardiometabolic risk, and weight in patients with T2DM; and Identify patients with T2DM who would benefit from incorporation of a GLP-1 RA into their overall treatment plan.

Visit https://www.peervoice.com/RSW860 to view the entire programme with slides. After completing “Sarah Jarvis, MBE, FRCGP - Achieving Shared Goals Across the Spectrum of CKD and HF”, participants will be able to: Identify patients at risk for and with chronic kidney disease (CKD) and heart failure (HF) based on early clinical indicators to expedite diagnosis and interventions; Recognise common barriers to evidence-based implementation of SGLT2 inhibition and strategies to overcome them; and Manage patients at risk for and with CKD and HF using a collaborative multidisciplinary approach.

Visit https://www.peervoice.com/QGT860 to view the entire programme with slides. After completing “Janaka Karalliedde, FRCP, PhD - Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs”, participants will be able to: Discuss the burden of stroke in patients with type 2 diabetes mellitus (T2DM) and recognise features of stroke in patients at risk; Analyse the safety and efficacy of GLP-1 receptor agonists (RAs) for the prevention of stroke in patients with T2DM; and Translate current guideline recommendations for stroke prevention in patients with T2DM into practical management plans.

Visit https://www.peervoice.com/ANV860 to view the entire programme with slides. After completing “Melanie J. Davies, CBE, FRCP, FMedSci - Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes”, participants will be able to: Recognise the impact of type 2 diabetes (T2DM) on stroke risk; Differentiate between the patterns and characteristics of stroke in people with T2DM compared to those without; and Apply practical strategies for managing stroke risk in patients with T2DM.

Visit https://www.peervoice.com/GYQ860 to view the entire programme with slides. After completing “Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure”, participants will be able to: Evaluate the impact of hyperkalaemia and its implications for cardiovascular and renal protection and disease management; Apply current evidence and guidance for the use of potassium binders to enable optimisation of recommended therapies, such as renin angiotensin aldosterone system inhibition (RAASi), in patients at risk for and with heart failure (HF) and/or chronic kidney disease (CKD); and Design practical strategies for the long-term management of chronic hyperkalaemia which optimise safety, efficacy, quality of life, and overall patient outcomes.

Visit https://www.peervoice.com/BPC860 to view the entire programme with slides. After completing “Sarah Jarvis, MBE, FRCGP - Identifying Intervention Points in CKD and HF From Multidisciplinary Viewpoints”, participants will be able to: Evaluate the impact of early identification and intervention on overall progression and outcomes of chronic kidney disease (CKD) and heart failure (HF); Recognise key points in the disease course of CKD and HF at which intervention is warranted to improve overall patient outcomes; and Propose evidence-based interventions to change the trajectory of the development and progression of CKD and HF.

Visit https://www.peervoice.com/SMM860 to view the entire programme with slides. After completing “Verónica Vázquez Velázquez, PhD - Optimising Obesity Care in Adolescent Patients: Practical Blueprints to Overcome Barriers”, participants will be able to: Recognise the consequences of obesity on short- and long-term adolescent health; Apply recommended strategies for communicating treatment goals and therapeutic options with adolescent patients with obesity and their families or caregivers; and Explain the rationale for intensified therapy in adolescents with obesity.

Visit https://www.peervoice.com/TUZ860 to view the entire programme with slides. After completing “George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs”, participants will be able to: Describe the role of nonsteroidal mineralocorticoid receptor antagonists (MRAs) as part of an overall treatment strategy to improve renal and cardiovascular outcomes for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM); Outline the emerging standards of care for management of patients with CKD and T2DM, based on the “four-pillar” approach; Explain the rationale for the recent updates in management guidelines for patients with CKD and T2DM; and Apply clinical evidence and recommendations to practice in the management of patients with CKD and T2DM, highlighting the role of nonsteroidal MRAs.

Visit https://www.peervoice.com/XAA860 to view the entire programme with slides. After completing “Luis Alberto Moreno, MD, PhD / Aaron Kelly, PhD - Assessing and Alleviating the Weight of Obesity in Adolescent Patients”, participants will be able to: Describe the burden and long-term effects of adolescent obesity; Discuss the benefits and limitations of current obesity care strategies in adolescent patients with obesity; and Evaluate the potential impact of emerging therapies on obesity in adolescent patients.

Visit https://www.peervoice.com/GVG860 to view the entire programme with slides. After completing “Kevin Fernando, FRCGP, FRCP Edin., FAcadMEd - Simplified Strategies to Optimise Obesity Management for Primary Point of Contact Clinicians”, participants will be able to: Recognise the role of novel pharmacologic options in the current management paradigm for obesity; Apply guidelines and evidence to improve weight management and outcomes in patients with obesity; and Use practical approaches to improve the management of patients with obesity within their clinical practice.

Visit https://www.peervoice.com/AFX860 to view the entire programme with slides. After completing “Angela Fitch, MD, FACP, Dipl. ABOM - Give the Heart a Break: Improving Cardiovascular Risk and Outcomes With Modern Weight Management Strategies”, participants will be able to: Define the impact of obesity on cardiovascular (CV) risk and the development of and mortality from CV disease; Discuss the role of anti-obesity medications, including GLP-1 receptor agonists (RAs), in the management of obesity-related CV risk; and Design evidence- and guideline-based therapy plans which can improve CV outcomes through improved management of patient weight within clinical practice.

Visit https://www.peervoice.com/WJJ860 to view the entire programme with slides. After completing “Kausik Ray, MD, MPhil (Cantab), MBChB - Taking Obesity to Heart: The Role of the Cardiologist in Incorporating Obesity Care Into Cardiovascular Care to Enhance Patient Outcomes”, participants will be able to: Identify the importance of early and effective weight management for patients with comorbid cardiovascular disease (CVD) and obesity; Evaluate current pharmacologic options for improving weight management and cardiovascular risk reduction in patients with CVD and obesity; and Apply practical, guideline-driven strategies for improving clinical outcomes in patients with CVD and obesity.

Visit https://www.peervoice.com/DVE860 to view the entire programme with slides. After completing “Samuel Seidu, MD, FRCGP, FRCP (Edin) - The Power of the Primary Point of Contact: Taking Obesity From Obstacle to Opportunity”, participants will be able to: Recognise the significance and long-term consequences of obesity and weight bias; Manage patients with obesity using the principles of chronic disease state management; and Assess the impact of recommended pharmacologic interventions on health outcomes and quality of life in patients with obesity.

Visit https://www.peervoice.com/YUP860 to view the entire programme with slides. After completing “Jens Lundgren, MD - Applying Current European Guidance on Treating COVID-19 in Hospitalized Patients”, participants will be able to: Identify which patients hospitalised for a reason other than COVID-19 (but have mild/moderate COVID-19 symptoms) require antiviral therapy; Explain the rationale for not using a corticosteroid in patients hospitalised with COVID-19 who do not require supplemental oxygen; Use effective, evidence-based strategies to optimise outcomes of patients hospitalised with COVID-19 who require conventional supplemental oxygen; Summarise the current European treatment guidelines for the treatment of COVID-19 in patients who require CPAP (continuous positive airway pressure) or HFNO (high flow nasal oxygen); and Apply the current European treatment recommendations for patients with COVID-19 who require mechanical ventilation or ECMO (extracorporeal membrane oxygenation).

Visit https://www.peervoice.com/WYS860 to view the entire programme with slides. After completing “Sharon Cohen, MD, FRCPC - Inflammation and the Brain: Why We Need To Know More”, participants will be able to: Explain the role of neuroinflammation in Alzheimer’s disease (AD); Identify the cells involved in driving chronic neuroinflammation; and Describe the vascular and systemic contributors to neuroinflammation.

Visit https://www.peervoice.com/AVK860 to view the entire programme with slides. After completing “Mauro Bernardi, MD - The Functional Quality of Albumin in Fluid Management of Patients with Liver Cirrhosis: Just a Concept or Does it Matter?”, participants will be able to: Explain the concept of functional quality of albumin; Describe the importance of the non-oncotic properties of albumin in the management of patients with liver cirrhosis; and Propose how functional quality of albumin may impact the management of patients with liver cirrhosis.

Visit https://www.peervoice.com/VXJ860 to view the entire programme with slides. After completing “Tali Cukierman-Yaffe, MD, MSc - Beyond Metabolic Benefits: Recognising and Reducing the Risk of Stroke in Type 2 Diabetes With GLP-1 RAs”, participants will be able to: Recognise the burden of stroke in patients with type 2 diabetes mellitus (T2DM) and opportunities to improve primary and secondary prevention; Design treatment regimens for T2DM in accordance with national guidelines which will optimise cardiovascular benefits and stroke risk reduction; and Identify strategies to improve stroke prevention and use of GLP-1 receptor agonists (RAs) through collaborative multidisciplinary management.

Visit https://www.peervoice.com/RCP860 to view the entire programme with slides. After completing “Melanie J. Davies, CBE, FRCP, FMedSci - Clinical Challenges in Insulin Initiation: Overcoming Obstacles to Improved Glycaemic Control in Type 2 Diabetes”, participants will be able to: Apply current clinical treatment guidelines to achieve timely glycaemic control in patients with type 2 diabetes mellitus (T2DM); Identify strategies to overcome common barriers to the use of basal insulin therapy; and Evaluate the potential place in therapy for novel basal insulins in the management of patients with T2DM.

Visit https://www.peervoice.com/TTP860 to view the entire programme with slides. After completing “Aoife Egan, MB, BCh, PhD - Insulin Resistance and Women’s Health: Case Studies in Gestational Diabetes and Polycystic Ovarian Syndrome”, participants will be able to: Discuss the importance of therapeutic intervention in patients with insulin resistance and gestational diabetes (GDM) or polycystic ovary syndrome (PCOS); Explain current evidence for anti-hyperglycaemic therapies for the management of patients with GDM and PCOS; and Formulate management plans that optimise long-term outcomes for patients with GDM and PCOS.

Visit https://www.peervoice.com/XUP860 to view the entire programme with slides. After completing “"Pantelis Sarafidis, MD, MSc, PhD - Meeting the Challenge of Improving Outcomes in CKD and T2DM: A Call to Action for Clinicians "”, participants will be able to: Describe the role of nonsteroidal mineralocorticoid receptor antagonists (MRAs) as part of an overall treatment strategy to improve renal and cardiovascular outcomes for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM); Outline the emerging standards of care for management of patients with CKD and T2DM, based on the “four-pillar” approach; and Explain the rationale for the recent updates in management guidelines for patients with CKD and T2DM.

Visit https://www.peervoice.com/QGF860 to view the entire programme with slides. After completing “Metabolic Health of PLWH: What Needs to Be Considered When Initiating or Switching ART?”, participants will be able to: Identify why people living with HIV (PLWH) are at increased risk of metabolic problems; Discuss the clinical data for antiretroviral therapies (ARTs) on metabolic health parameters; and Propose how best to manage PLWH who are at high risk of poor metabolic health and cardiovascular outcomes.

Visit https://www.peervoice.com/TAW860 to view the entire programme with slides. After completing “Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World”, participants will be able to: Describe the recent developments in the management of long-chain fatty acid oxidation disorders (LC-FAOD); Identify the patient characteristics and disease manifestations that would indicate a need to initiate a novel therapeutic approach to managing LC-FAOD; and Formulate practical approaches to optimise the management of patients with LC-FAOD on a novel therapy.